Trajectories of Mini-Mental State Examination Scores over the Lifespan in General Populations: A Systematic Review and Meta-Regression Analysis.
Conclusions: Between the age of 29 and 105 years MMSE scores decline, with the highest decline between age 84 and 105 years.Clinical Implementations: The use of MMSE should be restricted to higher age categories in aging general populations. PMID: 32374211 [PubMed - as supplied by publisher]
CONCLUSION: Frequent engagement in late life cognitive activity may help maintain decision-making among older persons, particularly among those with lower levels of cognitive function. PMID: 32646635 [PubMed - as supplied by publisher]
Authors: PMID: 32643872 [PubMed - in process]
CONCLUSIONS: This panel of 6 markers in blood serum may indicate underlying neurodegenerative processes in patients with AD at the MCI stage. The authors assume that a deranged equilibrium of neuroprotective and inflammatory processes is an overall major cause for neurodegeneration and cognitive decline. PMID: 32649324 [PubMed - as supplied by publisher]
With interest, we read the study of Mangino et al (Am J Geriatr Psychiatry 28:4 (2020) 466-477) in which they reviewed 75 cases of euthanasia and assisted suicide (EAS) in persons with dementia in the Netherlands published by the Dutch regional euthanasia review committees (RTE) (2011-2018). This overview indeed offers an unique insight into aspects of current practice, on an individual patient level. However, a number of issues need to be taken into account more explicitly when interpreting this report.
We thank Marijnissen et al.1 for their thoughtful comments and an opportunity to provide additional context to our paper.2 Their letter, however, includes some errors and potentially misleading statements. They begin by asserting that we mischaracterized the EAS review process. They quote us as describing the review as “afterwards reviewing a self-report subjective report of the physician.”1 What we actually wrote, which remains accurate, was: “…the retrospective oversight system relies on self-reports by physicians involved in the EAS process.”2
The introduction of psychotropic drugs in the 1950s revolutionized the understanding and treatment of severe psychiatric disorders, undoubtedly alleviating the symptom burden and improving daily functioning for persons with severe affective and psychotic disorders1. Today, these drugs are often used off-label, thus the use of psychotropic drugs for managing behavioral and psychological symptoms of dementia (BPSD) warrants special attention2-5. BPSD such as delusions, hallucinations, agitation, anxiety, and aberrant motor behavior are associated with poorer physical and cognitive functioning as symptoms persist and reoccur ...
Authors: Stepien K, Furczynska P, Zalewska M, Nowak K, Wlodarczyk A, Owsianka I, Skorek P, Zalewski J, Nessler J Abstract BACKGROUND: Recently heart failure (HF) has been found to be a new dementia risk factor, nevertheless their relations in patients following HF decompensation remain unknown. We sought to investigate whether a screening diagnosis for dementia (SDD) in this high-risk population may predict unfavorable long-term clinical outcomes. METHODS: 142 patients following HF decompensation requiring hospitalization were enrolled. Within a median time of 55 months all patients were screened for dementia w...
Conditions: Cognitive Impairment; Stroke; Dementia Intervention: Behavioral: Self-monitoring and personalized feedback on smartphone app Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Conditions: Alzheimer Disease; Dementia; Mild Cognitive Impairment Intervention: Sponsor: UsAgainstAlzheimer's Recruiting
Older adults with higher levels of a specific protein in their blood have better cognitive function and might be at lower risk for dementia than those with lower levels, according to a study published on Friday.